505 results on '"Klintmalm G"'
Search Results
2. De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial
3. Deceased donor uterus retrieval: A novel technique and workflow
4. Living Donor Uterus Transplantation: A Single Centerʼs Observations and Lessons Learned From Early Setbacks to Technical Success
5. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation
6. An Early Regional Experience with Expansion of Milan Criteria for Liver Transplant Recipients
7. Impact of IgG3 Subclass and C1q-Fixing Donor-Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation
8. Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
9. Whole Blood mRNA to Detect Hepatic Inflammation and Fibrosis in Post-Liver Transplant Patients With HCV.: Abstract# D2356
10. Preformed Class I DSA Testing: Standard vs. C1q vs. IgG3 Subclass Test Performance Comparison.: Abstract# A15
11. Impairment of Renal Function at One Year After Liver Transplantation Is a Prognostic Factor for Mortality.: Abstract# C1985
12. Center Variation in Graft Failure Rates Is Greater for Simultaneous Liver Kidney Transplantation Than Liver Transplantation Alone.: Abstract# C1975
13. What Is The Value of Routine Ultrasonographic Screening for Renal Cell Carcinoma in Patients Currently Listed for Kidney Transplantation?: Abstract# C1783
14. BK Viral Infection in Kidney Transplantation: The Role of Induction Therapy.: Abstract# B1032
15. 2-Hit Hypothesis: A Second “Hit” Increases the Risk for Death in Liver Allograft Recipients With Preformed Donor Specific Alloantibodies.: Abstract# 2118
16. Feasibility and Benefit of Minimization and Withdrawal of Immunosuppression (IS) Early After Liver Transplantation in HCV Positive Recipients.: Abstract# 2959
17. Intraoperative Hemodynamics and Development of Renal Dysfunction After Liver Transplantation in Recipients With Normal Renal Function.: Abstract# 2190
18. The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation
19. De Novo Donor-Specific HLA Antibodies Decrease Patient and Graft Survival in Liver Transplant Recipients
20. Presence of Preformed IgG3 DSA Identifies Patients at Higher Risk of Early Rejection in Liver Transplantation.: Abstract# D1602
21. Class II Alloantibody and Mortality in Simultaneous Liver-Kidney Transplantation
22. Transplant Organizational Structures: Viewpoints From Established Centers
23. Bortezomib for Acute Antibody-Mediated Rejection in Liver Transplantation
24. The Financial Cost of Mandatory Data Reporting: A Non-Reimbursable Burden for Transplant Centers.: Abstract# 1698: Poster Board #-Session: P260-IV
25. Factors Affecting Return To Work after Liver Transplantation.: Abstract# 1697: Poster Board #-Session: P259-IV
26. Renal Outcomes after Liver Transplantation for Acute Liver Failure.: Abstract# 1643: Poster Board #-Session: P205-IV
27. Instant Blood Mediated Inflammatory Reaction Occurs Even in Autologous Islet Transplantation.: Abstract# 1156 Poster Board #-Session: P23-III
28. Improved Renal Transplant Outcome in Polyoma Viral Infection with the Combination of Low Dose Cidofovir and Leflunomide: A Single Center Experience.: Abstract# 1102: Poster Board #-Session: P267-II
29. High Mean Fluorescence Intensity DSA and IgG3 Subclass DSA after Liver Transplantation Decrease Graft and Patient Survival.: Abstract# 857 Poster Board #-Session: P22-II
30. High MFI Preformed Class I and De Novo Class II Donor Specific Antibodies Accelerate Fibrosis Progression after Liver Transplant in HCV-Infected Patients.: Abstract# 782 Poster Board #-Session: P250-I
31. Lower Incidence of Acute Cellular Rejection in Liver Transplant Recipients More Than 60 Years of Age Allows Minimization of Immunosuppression.: Abstract# 760 Poster Board #-Session: P228-I
32. HBV Reinfection after Liver Transplant Is Associated with Increased Recurrent Hepatocellular Carcinoma and Worse Survival.: Abstract# 566: Poster Board #-Session: P34-I
33. Poster Board #-Session: P26-I Initial Outcomes of ITN030ST: Early Post-Liver Transplant Immunosuppression Withdrawal.: Abstract# 558
34. Preformed MHC Class II DSA Increases the Risk of Liver but Not Kidney Rejection after Simultaneous Liver-Kidney Transplant.: Abstract# 335
35. Multicenter Review of Liver Transplant for Hepatitis B Related Liver Disease: Females and Black Americans Do Worse.: Abstract# 195
36. High MFI De Novo MHC Class II Donor Specific Antibody Formation Impairs Patient Survival after Liver Transplantation.: Abstract# 141
37. Treat Patients, Not Statistics
38. Plasma proteolytic activity in liver transplant rejection
39. Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus-Based Immunosuppression
40. High Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies Associated With Chronic Rejection Postliver Transplant
41. Immunosuppression, Generic Drugs and the FDA
42. American Society of Transplant Surgeons’ White Paper: Impact of Closed ICUs on Transplant Patients’ Care
43. Transplant Surgery Fellow Perceptions About Training and the Ensuing Job Market—Are the Right Number of Surgeons Being Trained?
44. The Declaration of Istanbul: Review and Commentary by the American Society of Transplant Surgeons Ethics Committee and Executive Committee
45. ASTS Recommended Practice Guidelines for Controlled Donation after Cardiac Death Organ Procurement and Transplantation
46. Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients
47. American Society of Transplant Surgeons Transplant Center Outcomes Requirements—A Threat to Innovation
48. Poster Board #-Session: P224-II Tolerability of Mycophenolate Mofetil/Sirolimus Maintenance Therapy after Calcineurin Inhibitor Withdrawal in Liver Transplant Recipients: 1-Year Outcomes of the Spare-the-Nephron (STN) Trial.: Abstract# 1204
49. Transplantation Oversight—Finding the Right Balance Between the Layperson, the Transplant Professional and the Regulator
50. Conversion of Stable Liver Transplant Recipients From a Twice-Daily Prograf-Based Regimen to a Once-Daily Modified Release Tacrolimus-Based Regimen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.